Altitude sickness epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Line 13: Line 13:


===Prevalence===
===Prevalence===
*The prevalence of altitude sickness is approximately as following:<ref name="pmid21718562">{{cite journal |vauthors=Murdoch D |title=Altitude sickness |journal=BMJ Clin Evid |volume=2010 |issue= |pages= |date=March 2010 |pmid=21718562 |pmc=2907615 |doi= |url=}}</ref>
*The prevalence of altitude sickness is approximately as following:<ref name="pmid21718562">{{cite journal |vauthors=Murdoch D |title=Altitude sickness |journal=BMJ Clin Evid |volume=2010 |issue= |pages= |date=March 2010 |pmid=21718562 |pmc=2907615 |doi= |url=}}</ref><ref name="pmid21190503">{{cite journal |vauthors=Mairer K, Wille M, Burtscher M |title=The prevalence of and risk factors for acute mountain sickness in the Eastern and Western Alps |journal=High Alt. Med. Biol. |volume=11 |issue=4 |pages=343–8 |date=2010 |pmid=21190503 |doi=10.1089/ham.2010.1039 |url=}}</ref>
**9000 per 100,000 individuals of people at 2850 m  
**9000 per 100,000 individuals of people at 2850 m  
**13000 per 100,000 individuals of people at 3050 m  
**13000 per 100,000 individuals of people at 3050 m  

Revision as of 14:20, 7 March 2018

Altitude sickness Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Altitude Sickness from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Altitude sickness epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Altitude sickness epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Altitude sickness epidemiology and demographics

CDC on Altitude sickness epidemiology and demographics

Altitude sickness epidemiology and demographics in the news

Blogs on Altitude sickness epidemiology and demographics

Directions to Hospitals Treating Altitude sickness

Risk calculators and risk factors for Altitude sickness epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

With a rapid ascension to high altitudes in 1 to 3 days, more than 50% of people develop altitude sickness. The incidence of clinical HAPE in unacclimatized travelers exposed to high altitude (~ 4,000 m) appears to be less than 1%. In over 30 years of research experience, the U.S. Army Pike's Peak Research Laboratory, utilizing about 300 sea-level resident volunteers (and more than 100 staff members) rapidly and directly exposed to high altitude, only 3 were evacuated with suspected HAPE.

Epidemiology and Demographics

Incidence

  • The incidence of altitude sickness is approximately 53,000 per 100,000 individuals worldwide.[1][2]

Prevalence

  • The prevalence of altitude sickness is approximately as following:[2][3]
    • 9000 per 100,000 individuals of people at 2850 m
    • 13000 per 100,000 individuals of people at 3050 m
    • 34000 per individuals of people at 3650 m
    • 53,000 per 100,000 individuals of people at 4559 m

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

  • Patients of all age groups may develop [disease name].
  • The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
  • [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
  • [Chronic disease name] is usually first diagnosed among [age group].
  • [Acute disease name] commonly affects [age group].

Race

  • There is no racial predilection to [disease name].
  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References

  1. Hackett PH, Rennie D, Levine HD (November 1976). "The incidence, importance, and prophylaxis of acute mountain sickness". Lancet. 2 (7996): 1149–55. PMID 62991.
  2. 2.0 2.1 Murdoch D (March 2010). "Altitude sickness". BMJ Clin Evid. 2010. PMC 2907615. PMID 21718562.
  3. Mairer K, Wille M, Burtscher M (2010). "The prevalence of and risk factors for acute mountain sickness in the Eastern and Western Alps". High Alt. Med. Biol. 11 (4): 343–8. doi:10.1089/ham.2010.1039. PMID 21190503.

Template:WH Template:WS